KCT0002346招募中未知
Effect of DW2009 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 55(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •(1)Physically healthy men and women aged between 55 and 85 years old who complain of memory loss
- •(2)A person who is capable of Korean
- •(3) A person who complain of memory loss and demonstrate a decrease of 1.0 SD or more on CERAD-K (Consortium to Establish a Registry for Alzheimer's Disease-Korean version)
- •(4)A person who has agreed to participate in this Clinical trial before signing the human body test and has signed an informed consent
排除标准
- •(1) People who has medical history of malignant tumors, severe cardiovascular diseases (stroke, hemorrhage, etc), and sever heart diseases (angina, myocardial infarction, heart failure, arrhythmias requiring treatments). However, people who have a history of cardiovascular diseases but are clinically stable can participate in the study.
- •(2) People who are currently suffering from schizophrenia or have a history of schizophrenia
- •(3) People who have major depressive disorders categorized by DSM-V(The Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition)
- •(4) People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on DSM-V)
- •(5) People who have taken medications for Alzheimer’s disease or other cognitive function problems within 4 weeks prior to the first visit of the study. The examples of the medications are Antipsycotics, Neurodegenerative Disease Drugs, Nootropics & Neurotonics, and tricyclic antidepressant.
- •(6) People with a daily intake of more than 400 IU vitamin E
- •(7) People who have received estrogen replacement therapy within the first two months prior to the first visit of the study
- •(Except for topical coverage)
- •(8) People who have taken the purposes of improving cognitive function within the first two weeks prior to the first visit of the study
- •(9) People with alcohol abuse or alcohol dependence
- •(10) People with thyroid disease (TSH of 0.1 uU/ml or less, or TSH of 10 uU/ml or higher)
- •(11) People with renal dysfunction whose creatinine level is more than twice the upper limit of normal range
- •(12) People with dyshepatia or liver failure whose AST(GOT) or ALT(GPT) level is more than triple times the upper limit of normal range
- •(13) People with uncontrolled hypertension (160/100 mmHg or higher, After 10 minutes of stabilization, measurements are taken as a reference.)
- •(14) People with uncontrolled diabetes/blood sugar (fasting glucose of 180 mg/dl or higher)
- •(15) People who plan to become pregnant during pregnancy or during the Clinical trial period
- •(16) People who have participated in other clinical trials within the first three months of the study, or who plan to participate in other clinical trials since the start of the study
- •(17) The person who is deemed inappropriate by the Investigator
研究者
相似试验
已完成
不适用
Effect of WS-5 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, multi-center, Randomized, Double-blind, Placebo-Controlled Clinical TrialKCT0003695Chung-Ang Univerisity Hospital90
进行中（未招募）
不适用
Effect of PM-EE on the Mild cognitive decline for the Efficacy and Safety; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical TrialKCT0003418Seoul National University Hospital60
招募中
不适用
prospective study of mild cognitive impairment and dementia in Kurashiki.JPRN-UMIN000035971Kawasaki Medical School1,000
尚未招募
不适用
Investigation of mild cognitive impairment using 11C-PiBmild cognitive impairmentJPRN-UMIN000020512Kinki University Faculty of Medicine125
招募中
不适用
Effect of RP-1701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical TrialKCT0004042Kyung Hee University Hospital100